Target Price | $176.63 |
Price | $107.89 |
Potential |
63.71%
register free of charge
|
Number of Estimates | 17 |
17 Analysts have issued a price target Axsome Therapeutics, Inc. 2026 .
The average Axsome Therapeutics, Inc. target price is $176.63.
This is
63.71%
register free of charge
$216.00
100.20%
register free of charge
$148.00
37.18%
register free of charge
|
|
A rating was issued by 17 analysts: 17 Analysts recommend Axsome Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Axsome Therapeutics, Inc. stock has an average upside potential 2026 of
63.71%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 385.69 | 620.50 |
42.53% | 60.88% | |
EBITDA Margin | -63.39% | -15.56% |
2.58% | 75.45% | |
Net Margin | -75.59% | -21.69% |
20.25% | 71.30% |
16 Analysts have issued a sales forecast Axsome Therapeutics, Inc. 2025 . The average Axsome Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Axsome Therapeutics, Inc. EBITDA forecast 2025. The average Axsome Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Axsome Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Axsome Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -5.99 | -2.76 |
13.66% | 53.92% | |
P/E | negative | |
EV/Sales | 8.30 |
8 Analysts have issued a Axsome Therapeutics, Inc. forecast for earnings per share. The average Axsome Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Axsome Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
Needham |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
Needham |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
Locked
Needham:
Locked
➜
Locked
|
Apr 01 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
Mar 27 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
Locked
Needham:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.